3,9-dimethyl-1,2,3,4-tetrahydrocarbazole-4-one | 1242958-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,9-dimethyl-1,2,3,4-tetrahydrocarbazole-4-one
• 英文别名: 3,9-dimethyl-2,3-dihydro-1H-carbazol-4-one
• CAS: 1242958-58-2
• 化学式: C₁₄H₁₅NO
• 分子量: 213.279
• InChiKey: HSAVSQBEFHKYLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基-2,3,4,9-四氢-1H-咔唑 在 四丁基硫酸氢铵 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 3,9-dimethyl-1,2,3,4-tetrahydrocarbazole-4-one
  参考文献：
  名称：

  Gulle, Sibel; Ergun, Yavuz, Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5517 - 5522

  摘要：

  DOI：

文献信息

• Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
  申请人：Singh Nikhilesh N.

  公开号：US20080213363A1

  公开（公告）日：2008-09-04

  Compositions, methods, and formulations for delivering 5-HT 3 antagonists across the oral mucosa are described. In some variations, the described compositions comprise at least one 5-HT 3 antagonist, which is at least partly in an ionized form, and a buffer system. The buffer system generally comprises at least two different buffering agents and is capable of changing the pH of saliva from an arbitrary initial pH to a predetermined final pH, and of sustaining the final pH for a period of time. The predetermined final pH favors substantially complete conversion of the ionized form to the un-ionized form. In other variations, the described compositions comprise a 5-HT 3 antagonist, at least partly in an un-ionized form, and a buffer system. In these variations, the buffer system is capable of providing an adjusted salival pH such that the 5-HT 3 antagonist remains in its un-ionized form. Dissolving tablets are also described.
• METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA
  申请人：SINGH NIKHILESH N.

  公开号：US20100256210A1

  公开（公告）日：2010-10-07

  Methods for treating a patient with ondansetron are described. The method includes administering a solid pharmaceutical composition having ondansetron and a buffer to the patient. Ondansetron is absorbed across a permeable membrane of the patient's oral mucosa. The buffer may include two different buffering agents, such as sodium carbonate and sodium bicarbonate. The buffer may raise the pH of saliva to a pH of between 7.1 to 13. The patient may suffer from emesis, such as nausea and vomiting associated with cancer chemotherapy and radiotherapy.
• Gulle, Sibel; Ergun, Yavuz, Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5517 - 5522
  作者：Gulle, Sibel、Ergun, Yavuz

  DOI：——

  日期：——